Event Focuses on Cannabis Cultivation and Extraction Best Practices and Standards
DENVER, CO / ACCESSWIRE / June 28, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that CEO Tim Keogh will be speaking at Cannabis Community Care and Research Network's (C3RN) Cannabis Science and Education Series on Thursday, June 28 in Worcester, MA.
The event is part of C3RN's monthly Cannabis Science, Education, and Networking series in Massachusetts to showcase the latest cannabis innovations. The events attract diverse groups of leaders from within and outside of the cannabis industry, public health and policy experts and other businesses. Mr. Keogh will be speaking about best practices for cannabis cultivation, facility design and integrated pest management.
Tim Keogh, AmeriCann CEO, has spoken at cannabis industry conferences across the United States as an expert on topics including industry best practices, real estate development and the cannabis economy. In January of 2018, Marijuana Business Daily recognized Mr. Keogh as one of the "Top People to Watch in 2018."
AmeriCann is developing the Massachusetts Medical Cannabis Center (MMCC), a state-of-the-art cannabis cultivation and processing development in the midst of the rapidly growing Massachusetts medical cannabis market. The MMCC project is approved for 1 million square feet, which will be developed in phases and is expected to be one of the most technologically advanced cultivation facilities in the nation.
Massachusetts is poised to allow adult-use cannabis, allowing any adult over 21 years old to purchase cannabis, in addition to the existing medical cannabis market. Industry experts believe it will become the epicenter for cannabis innovation and research for the entire northeast US with annual sales of over $1 billion by 2020.
About AmeriCann
AmeriCann (OTCQB: ACAN) is a publicly traded Agricultural Technology (Ag-Tech) company that is developing a new generation of sustainable, state-of-the-art medical cannabis cultivation and processing properties.
AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company's commitment to social and environmental ethics, transparency and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at: www.americann.co, or follow AmeriCann on Twitter @ACANinfo.
About Massachusetts Medical Cannabis Center (MMCC)
AmeriCann's flagship project, The Massachusetts Medical Cannabis Center, is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. Voters in Massachusetts approved legalizing the adult use of recreational marijuana in November of 2016. The state is on track to open the first cannabis storefronts for Adult-Use by July 1, 2018, making Massachusetts the first state in the Northeast to legalize adult-use cannabis.
AmeriCann's Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures. The company is planning to replicate the Cannopy platform in additional states.
The first phase of the MMCC project consists of 30,000 sq. ft. of cultivation, processing and research facility.
About Cannabis Community Care and Research Network (C3RN)
Cannabis Community Care and Research Network (C3RN) is an public benefit corporation (B Corp) based out of Somerville, MA that specializes in providing high-quality research and analytic services related to the impacts of medical and adult-use recreational cannabis. As a social justice-oriented research and analytics company, C3RN specializes in designing, monitoring, and evaluating models of integrating adult-use and medical cannabis to positively impact social, clinical, and public health outcomes. C3RN has over 80 years of collective experience in cannabis, healthcare, life sciences, chemistry, public health, data science, and academic research. C3RN provides cannabis and health research and data analytic services, and consulting around cultivation, extraction, life sciences, technology, and medical cannabis patient care. C3RN runs a monthly Cannabis Science, Education, and Networking series in Massachusetts to showcase the latest cannabis innovations, evidence, and best practices. For more information about C3RN's research, events, and services, please visit: www.cannaresearchnetwork.com or contact Dr. Marion McNabb, CEO of C3RN at [email protected]
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's Registration Statement on Form S-1, which the Company recently filed with the SEC and which may be viewed at www.sec.gov.
Contact Information:
Corporate:
AmeriCann, Inc.
1550 Wewatta St.
Denver, CO 80206
(303) 862-9000
[email protected]
www.americann.co
@ACANinfo on Twitter
Investors:
Hayden IR
[email protected]
(917) 658-7878
SOURCE: AmeriCann, Inc.